Skip to content

Study · Non-randomized trial · n = 25 · 1988

10 results

The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism.

Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, Christiansen C

The Journal of clinical endocrinology and metabolism1 Oct 1988Cited by 100 (Europe PMC)

PMID2971080 (opens in a new tab)DOI10.1210/jcem-67-4-701 (opens in a new tab)PepBankPUB-02971080
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In premenopausal women, biochemical bone turnover estimates significantly increased to postmenopausal levels in both nafarelin dose groups.

    In plain wordsIn premenopausal women, bone turnover markers increased to postmenopausal levels in both nafarelin dose groups.

    Peptide
    Nafarelin
    Outcome
    IncreaseBone turnover
    Study

    n = 25

    Comparator
    Pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 or 400 micrograms/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    In both treatment groups the biochemical estimates of bone turnover increased significantly to postmenopausal levels.
    1 context sentence
    Summary · context
    The effect on bone metabolism of an agonist analog of GnRH, nafarelin, was studied in 16 premenopausal women, who received 200 micrograms nafarelin/day for 6 months, and 9 premenopausal women, who received 400 micrograms nafarelin/day for 6 months, followed by a 6-month follow-up period.
  2. 02HumanNon-randomized trialSafety outcome

    In premenopausal women, bone mineral measurements did not change throughout nafarelin 200 micrograms/day treatment and follow-up.

    In plain wordsIn premenopausal women, bone mineral measurements did not change during or after nafarelin 200 micrograms/day.

    Peptide
    Nafarelin
    Outcome
    No significant changeBone mineral measurements
    Study

    n = 16

    Comparator
    Pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 micrograms/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The bone mineral measurements in the 200 micrograms group did not change throughout the study.
    1 context sentence
    Summary · context
    The effect on bone metabolism of an agonist analog of GnRH, nafarelin, was studied in 16 premenopausal women, who received 200 micrograms nafarelin/day for 6 months, and 9 premenopausal women, who received 400 micrograms nafarelin/day for 6 months, followed by a 6-month follow-up period.
  3. 03HumanNon-randomized trialSafety outcome

    In premenopausal women, forearm bone mineral content significantly decreased after 6 months of nafarelin 400 micrograms/day.

    In plain wordsIn premenopausal women, forearm bone mineral content decreased after 6 months of nafarelin 400 micrograms/day.

    Peptide
    Nafarelin
    Outcome
    DecreaseForearm mineral content
    Study

    n = 9

    Comparator
    Pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 micrograms/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Bone mineral content in the forearm (measured by single photon absorptiometry) and in the spine (measured by dual photon absorptiometry) significantly decreased after 6 months of treatment with 400 micrograms nafarelin, but 6 months after termination of treatment all bone mineral measurements had re…
    1 context sentence
    Summary · context
    The effect on bone metabolism of an agonist analog of GnRH, nafarelin, was studied in 16 premenopausal women, who received 200 micrograms nafarelin/day for 6 months, and 9 premenopausal women, who received 400 micrograms nafarelin/day for 6 months, followed by a 6-month follow-up period.
  4. 04HumanNon-randomized trialSafety outcome

    In premenopausal women, spinal bone mineral content significantly decreased after 6 months of nafarelin 400 micrograms/day.

    In plain wordsIn premenopausal women, spinal bone mineral content decreased after 6 months of nafarelin 400 micrograms/day.

    Peptide
    Nafarelin
    Outcome
    DecreaseSpine mineral content
    Study

    n = 9

    Comparator
    Pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 micrograms/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Bone mineral content in the forearm (measured by single photon absorptiometry) and in the spine (measured by dual photon absorptiometry) significantly decreased after 6 months of treatment with 400 micrograms nafarelin, but 6 months after termination of treatment all bone mineral measurements had re…
    1 context sentence
    Summary · context
    The effect on bone metabolism of an agonist analog of GnRH, nafarelin, was studied in 16 premenopausal women, who received 200 micrograms nafarelin/day for 6 months, and 9 premenopausal women, who received 400 micrograms nafarelin/day for 6 months, followed by a 6-month follow-up period.
  5. 05HumanNon-randomized trialSafety outcome

    In premenopausal women, all bone mineral measurements returned to pretreatment levels 6 months after nafarelin 400 micrograms/day ended.

    In plain wordsIn premenopausal women, bone mineral measurements returned to initial levels 6 months after nafarelin ended.

    Peptide
    Nafarelin
    Outcome
    Direction not reportedBone mineral recovery
    Study

    n = 9

    Comparator
    Pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 micrograms/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Bone mineral content in the forearm (measured by single photon absorptiometry) and in the spine (measured by dual photon absorptiometry) significantly decreased after 6 months of treatment with 400 micrograms nafarelin, but 6 months after termination of treatment all bone mineral measurements had re…
    1 context sentence
    Summary · context
    The effect on bone metabolism of an agonist analog of GnRH, nafarelin, was studied in 16 premenopausal women, who received 200 micrograms nafarelin/day for 6 months, and 9 premenopausal women, who received 400 micrograms nafarelin/day for 6 months, followed by a 6-month follow-up period.
  6. 06HumanNon-randomized trialSafety outcome

    In premenopausal women, urinary hydroxyproline to creatinine ratios decreased abruptly after nafarelin withdrawal.

    In plain wordsIn premenopausal women, a urinary bone breakdown marker decreased abruptly after nafarelin ended.

    Peptide
    Nafarelin
    Outcome
    DecreaseHydroxyproline to creatinine after withdrawal
    Study

    n: not reported in source

    Comparator
    During treatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 or 400 micrograms/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Withdrawal of treatment resulted in an abrupt decrease in the bone resorption parameters (fasting urinary hydroxyproline to creatinine and calcium to creatinine excretion ratios and serum phosphate), whereas there was a protracted fall in the bone formation parameters (plasma bone Gla protein and se…
    1 context sentence
    Summary · context
    The effect on bone metabolism of an agonist analog of GnRH, nafarelin, was studied in 16 premenopausal women, who received 200 micrograms nafarelin/day for 6 months, and 9 premenopausal women, who received 400 micrograms nafarelin/day for 6 months, followed by a 6-month follow-up period.
  7. 07HumanNon-randomized trialSafety outcome

    In premenopausal women, urinary calcium to creatinine ratios decreased abruptly after nafarelin withdrawal.

    In plain wordsIn premenopausal women, urinary calcium to creatinine ratios decreased abruptly after nafarelin ended.

    Peptide
    Nafarelin
    Outcome
    DecreaseCalcium to creatinine after withdrawal
    Study

    n: not reported in source

    Comparator
    During treatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 or 400 micrograms/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Withdrawal of treatment resulted in an abrupt decrease in the bone resorption parameters (fasting urinary hydroxyproline to creatinine and calcium to creatinine excretion ratios and serum phosphate), whereas there was a protracted fall in the bone formation parameters (plasma bone Gla protein and se…
    1 context sentence
    Summary · context
    The effect on bone metabolism of an agonist analog of GnRH, nafarelin, was studied in 16 premenopausal women, who received 200 micrograms nafarelin/day for 6 months, and 9 premenopausal women, who received 400 micrograms nafarelin/day for 6 months, followed by a 6-month follow-up period.
  8. 08HumanNon-randomized trialSafety outcome

    In premenopausal women, serum phosphate decreased abruptly after nafarelin withdrawal.

    In plain wordsIn premenopausal women, blood phosphate decreased abruptly after nafarelin ended.

    Peptide
    Nafarelin
    Outcome
    DecreaseSerum phosphate after withdrawal
    Study

    n: not reported in source

    Comparator
    During treatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 or 400 micrograms/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Withdrawal of treatment resulted in an abrupt decrease in the bone resorption parameters (fasting urinary hydroxyproline to creatinine and calcium to creatinine excretion ratios and serum phosphate), whereas there was a protracted fall in the bone formation parameters (plasma bone Gla protein and se…
    1 context sentence
    Summary · context
    The effect on bone metabolism of an agonist analog of GnRH, nafarelin, was studied in 16 premenopausal women, who received 200 micrograms nafarelin/day for 6 months, and 9 premenopausal women, who received 400 micrograms nafarelin/day for 6 months, followed by a 6-month follow-up period.
  9. 09HumanNon-randomized trialSafety outcome

    In premenopausal women, plasma bone Gla protein showed a protracted fall six months after withdrawal of nafarelin.

    In plain wordsIn premenopausal women, a bone formation protein decreased slowly six months after nafarelin ended.

    Peptide
    Nafarelin
    Outcome
    DecreaseBone Gla protein after withdrawal
    Study

    n: not reported in source

    Comparator
    During treatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 or 400 micrograms/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Withdrawal of treatment resulted in an abrupt decrease in the bone resorption parameters (fasting urinary hydroxyproline to creatinine and calcium to creatinine excretion ratios and serum phosphate), whereas there was a protracted fall in the bone formation parameters (plasma bone Gla protein and se…
    1 context sentence
    Summary · context
    The effect on bone metabolism of an agonist analog of GnRH, nafarelin, was studied in 16 premenopausal women, who received 200 micrograms nafarelin/day for 6 months, and 9 premenopausal women, who received 400 micrograms nafarelin/day for 6 months, followed by a 6-month follow-up period.
  10. 10HumanNon-randomized trialSafety outcome

    In premenopausal women, serum alkaline phosphatase showed a protracted fall six months after withdrawal of nafarelin.

    In plain wordsIn premenopausal women, alkaline phosphatase decreased slowly six months after nafarelin ended.

    Peptide
    Nafarelin
    Outcome
    DecreaseAlkaline phosphatase after withdrawal
    Study

    n: not reported in source

    Comparator
    During treatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 or 400 micrograms/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Withdrawal of treatment resulted in an abrupt decrease in the bone resorption parameters (fasting urinary hydroxyproline to creatinine and calcium to creatinine excretion ratios and serum phosphate), whereas there was a protracted fall in the bone formation parameters (plasma bone Gla protein and se…
    1 context sentence
    Summary · context
    The effect on bone metabolism of an agonist analog of GnRH, nafarelin, was studied in 16 premenopausal women, who received 200 micrograms nafarelin/day for 6 months, and 9 premenopausal women, who received 400 micrograms nafarelin/day for 6 months, followed by a 6-month follow-up period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.